| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde?
|
Cruz-Monteagudo, Maykel
|
|
2014
|
19 |
8 |
p. 1069-1080
12 p.
|
artikel
|
| 2 |
Adenosine and inflammation: what's new on the horizon?
|
Antonioli, Luca
|
|
2014
|
19 |
8 |
p. 1051-1068
18 p.
|
artikel
|
| 3 |
An overview of FDA-approved new molecular entities: 1827–2013
|
Kinch, Michael S.
|
|
2014
|
19 |
8 |
p. 1033-1039
7 p.
|
artikel
|
| 4 |
A potential role for GPR55 in the regulation of energy homeostasis
|
Simcocks, Anna C.
|
|
2014
|
19 |
8 |
p. 1145-1151
7 p.
|
artikel
|
| 5 |
Assessment of right ventricular responses to therapy in pulmonary hypertension
|
Spruijt, Onno A.
|
|
2014
|
19 |
8 |
p. 1246-1250
5 p.
|
artikel
|
| 6 |
A 21st-century approach to age-old problems: the ascension of biologics in clinical therapeutics
|
Espiritu, Michael J.
|
|
2014
|
19 |
8 |
p. 1109-1113
5 p.
|
artikel
|
| 7 |
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
|
Whang, Jennifer A.
|
|
2014
|
19 |
8 |
p. 1200-1204
5 p.
|
artikel
|
| 8 |
Cellular and molecular mechanisms of bone damage and repair in inflammatory arthritis
|
Swales, Catherine
|
|
2014
|
19 |
8 |
p. 1178-1185
8 p.
|
artikel
|
| 9 |
Cellular and molecular mechanisms of cartilage damage and repair
|
Sherwood, Joanna C.
|
|
2014
|
19 |
8 |
p. 1172-1177
6 p.
|
artikel
|
| 10 |
Changing role of formulation in biologics drug development
|
Saylor, Tom
|
|
2014
|
19 |
8 |
p. 1031-1032
2 p.
|
artikel
|
| 11 |
Considering a new paradigm for Alzheimer's disease research
|
Langley, Gillian R.
|
|
2014
|
19 |
8 |
p. 1114-1124
11 p.
|
artikel
|
| 12 |
Contents 1 continued pages 1-2 2
|
|
|
2014
|
19 |
8 |
p. ii-iii
nvt p.
|
artikel
|
| 13 |
Contents page 1
|
|
|
2014
|
19 |
8 |
p. i-
1 p.
|
artikel
|
| 14 |
Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed
|
James White, R.
|
|
2014
|
19 |
8 |
p. 1226-1229
4 p.
|
artikel
|
| 15 |
Endpoints in PAH clinical trials in the era of combination therapy: How do we decide whether something is working without going bankrupt?
|
McGlinchey, Neil
|
|
2014
|
19 |
8 |
p. 1236-1240
5 p.
|
artikel
|
| 16 |
Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies
|
Hornberg, Jorrit J.
|
|
2014
|
19 |
8 |
p. 1137-1144
8 p.
|
artikel
|
| 17 |
Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how
|
Hornberg, Jorrit J.
|
|
2014
|
19 |
8 |
p. 1131-1136
6 p.
|
artikel
|
| 18 |
High-throughput epitope binning of therapeutic monoclonal antibodies: why you need to bin the fridge
|
Brooks, Benjamin D.
|
|
2014
|
19 |
8 |
p. 1040-1044
5 p.
|
artikel
|
| 19 |
Histamine H4 receptor antagonists for the treatment of inflammatory disorders
|
Liu, Wai L.
|
|
2014
|
19 |
8 |
p. 1222-1225
4 p.
|
artikel
|
| 20 |
How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease
|
Tuder, Rubin M.
|
|
2014
|
19 |
8 |
p. 1257-1263
7 p.
|
artikel
|
| 21 |
Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first
|
Cohen-Kaminsky, Sylvia
|
|
2014
|
19 |
8 |
p. 1251-1256
6 p.
|
artikel
|
| 22 |
Inhibiting RORγt/Th17 axis for autoimmune disorders
|
Isono, Fujio
|
|
2014
|
19 |
8 |
p. 1205-1211
7 p.
|
artikel
|
| 23 |
miRNAs in PAH: biomarker, therapeutic target or both?
|
Meloche, Jolyane
|
|
2014
|
19 |
8 |
p. 1264-1269
6 p.
|
artikel
|
| 24 |
Mucus models to evaluate nanomedicines for diffusion
|
Groo, Anne-Claire
|
|
2014
|
19 |
8 |
p. 1097-1108
12 p.
|
artikel
|
| 25 |
Novel immunological targets in rheumatic diseases: clues from current therapies
|
D’Acquisto, Fulvio
|
|
2014
|
19 |
8 |
p. 1155-1160
6 p.
|
artikel
|
| 26 |
Pathogenesis of rheumatoid arthritis: from systemic autoimmunity to localised joint disease
|
Pitzalis, Costantino
|
|
2014
|
19 |
8 |
p. 1152-1154
3 p.
|
artikel
|
| 27 |
Peripheral and synovial mechanisms of humoral autoimmunity in rheumatoid arthritis
|
Corsiero, Elisa
|
|
2014
|
19 |
8 |
p. 1161-1165
5 p.
|
artikel
|
| 28 |
PI3K inhibitors as potential therapeutics for autoimmune disease
|
Ball, Jennifer
|
|
2014
|
19 |
8 |
p. 1195-1199
5 p.
|
artikel
|
| 29 |
Protein kinase C inhibitors for immune disorders
|
Altman, Amnon
|
|
2014
|
19 |
8 |
p. 1217-1221
5 p.
|
artikel
|
| 30 |
Recombinant probiotics with antimicrobial peptides: a dual strategy to improve immune response in immunocompromised patients
|
Mandal, Santi M.
|
|
2014
|
19 |
8 |
p. 1045-1050
6 p.
|
artikel
|
| 31 |
Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension
|
West, James
|
|
2014
|
19 |
8 |
p. 1241-1245
5 p.
|
artikel
|
| 32 |
Resolution of inflammation: examples of peptidergic players and pathways
|
Ahmed, Tazeen J.
|
|
2014
|
19 |
8 |
p. 1166-1171
6 p.
|
artikel
|
| 33 |
Resolution of inflammation: targeting GPCRs that interact with lipids and peptides
|
Cash, Jenna L.
|
|
2014
|
19 |
8 |
p. 1186-1192
7 p.
|
artikel
|
| 34 |
Search strategies and evaluation in protein–protein docking: principles, advances and challenges
|
Huang, Sheng-You
|
|
2014
|
19 |
8 |
p. 1081-1096
16 p.
|
artikel
|
| 35 |
Systems mapping of genes controlling chemotherapeutic drug efficiency for cancer stem cells
|
Wu, Weimiao
|
|
2014
|
19 |
8 |
p. 1125-1130
6 p.
|
artikel
|
| 36 |
Targeting autoimmunity: strategies and tactics
|
Masuda, Esteban S.
|
|
2014
|
19 |
8 |
p. 1193-1194
2 p.
|
artikel
|
| 37 |
Targeting IL-34 in chronic inflammation
|
Masteller, Emma L.
|
|
2014
|
19 |
8 |
p. 1212-1216
5 p.
|
artikel
|
| 38 |
Targeting the Wnt signaling pathways in pulmonary arterial hypertension
|
de Jesus Perez, Vinicio
|
|
2014
|
19 |
8 |
p. 1270-1276
7 p.
|
artikel
|
| 39 |
Thrombosis, platelets, microparticles and PAH: more than a clot
|
Lannan, Katie L.
|
|
2014
|
19 |
8 |
p. 1230-1235
6 p.
|
artikel
|
Tijdschrift beschrijving